GSK's 'functional cure' for hep B proves worth in phase 3 trials setting up approval push
Fuente:
FierceBiotech
GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, setting up the pharma for a push to the FDA.